Pfizer led the Roche-backed antibody developer's series C round, which boosted its overall funding to $66m.
US-based biotechnology company CytomX Therapeutics secured $20m in a series C round led by Pfizer Venture Investments, the corporate venturing unit of drugs company Pfizer, yesterday.
Roche Venture Fund, the corporate venturing arm of healthcare company Roche, also participated in the round alongside Third Rock Ventures and Canaan Partners.
CytomX previously secured $41m in a 2012 series B round that included Roche and Third Rock, and which was led by Canaan. It reportedly raised $5m in a 2009 series A…
